FEATURES OF EXPRESSION OF CD133 AND CD44 MARKERS OF TUMOR STEM CELLS WITH METASTATIC AND NON-METASTATIC GASTRIC CANCER

Background. Gastric cancer is the second leading cause of cancer-related death due to advanced disease. A special role in the pathogenesis and metastasis of the tumor is assigned to tumor stem cells (TSC ),  responsible for resistance to chemotherapy and radiotherapy and causing tumor progression.

Objective: to determine the CD 44 and CD 133 markers of TSC in tumor tissues of non-metastatic and metastatic gastric cancer using the immunohistochemical method.

Material and Methods. A prospective study of tumors in patients with gastric cancer was conducted: Group 1 – 20 people with T3–4aN0–3M0G2 tumor, average age 58.9 ± 9.7; Group 2 – 20 people with T3–4aN0–3M1G2 tumor, with metastases in the peritoneum, average age 53.4 ± 11.9. The expression of CD 44 and CD 133 in the tumor tissue was determined by immunohistochemistry.

Results. Differences were found in the number of tumor cells expressing the CD 44 marker in the presence and absence of metastases in patients with gastric cancer – their number was 10.0 ± 3.08 and 6.0 ± 2.3, respectively. The CD 133 molecule was detected in 100 % of cases having metastases, while in cases having no metastases, the marker was detected only in 80 % of cases. The average percentage of CD 133 + cells was 21.3 ± 11.6 % in patients with metastatic gastric cancer and 10.0 ± 2.4 % in patients having no metastases.

Conclusion. The degree of expression of the CD 44 and CD 133 markers had characteristic differences in patients with gastric cancer, which can be used further to explain the results of the treatment and the prognosis of the disease.

1. Kaprin A.D., Starinskiy V.V., Petrova G.V. The state of cancer care for the population of Russia in 2016. Moscow, 2017. 236 p. (in Russian).

2. Kit O.I., Gevorkyan Yu.A., Soldatkina N.V., Novikova I.A., Gusareva M.A., Kozhushko M.A. Molecular and morphological effects of preoperative hypofractionation for rectal cancer. Molecular medicine. 2017; 15(2): 39–43. (in Russian).

3. Nikipelova E.A., Kit O.I., Shaposhnikov A.V., Zlatnik E.Yu., Novikova I.A., Vladimirova L.Yu., Pozdnyakova V.V., Lysenko I.B., Shevchenko A.N., Demidova A.A. Immunologic criteria for the development of distant metastases from colon cancer. Science journal. Bulletin of Higher Education Institutes. North Caucasus Region. Natural Sciences. 2017; 3–2 (195–2): 96–101. (in Russian).

4. Kim W.T., Ryu C.J. Cancer stem cell surface markers on normal stem cells. BMB Rep. 2017 Jun; 50(6): 285–298. doi: 10.5483/bmbrep.2017.50.6.039.

5. Meacham C.E., Morrison S.J. Tumour heterogeneity and cancer cell plasticity. Nature. 2013 Sep 19; 501(7467): 328–37. doi: 10.1038/nature12624.

6. Wang J.Y., Chang C.C., Chiang C.C., Chen W.M., Hung S.C. Silibinin suppresses the maintenance of colorectal cancer stem-like cells by inhibiting PP2A/AKT/mTOR pathways. J Cell Biochem. 2012 May; 113(5): 1733–43. doi: 10.1002/jcb.24043.

7. Yeung T.M., Gandhi S.C., Wilding J.L., Muschel R., Bodmer W.F. Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci USA. 2010 Feb 23; 107(8): 3722–7. doi: 10.1073/pnas.0915135107.

8. Louderbough J.M., Schroeder J.A. Understanding the dual nature of CD44 in breast cancer progression. Mol Cancer Res. 2011 Dec; 9(12): 1573–86. doi: 10.1158/1541-7786.MCR-11-0156.

9. Puchinskaya M.V. Cancer stem cell markers and their prognostic value. Pathology Archive, 2016; 2: 47–54. (in Russian).

10. Zlatnik E.Yu., Kit O.I., Novikova I.A., Ulyanova E.P., Sagakyants A.B., Teplyakova M.A., Egorov G.Y., Chupanov G.M., Chernikova E.N. The possible role of cancer stem cells in metastatic process of colorectal cancer. 2018. 6. [Internet]. URL: http://www.science-education.ru/ru/article/view?id=28217 (cited 28.05.2019). (in Russian).

11. Afify A., Durbin-Johnson B., Virdi A., Jess H. The expression of CD44v6 in colon: from normal to malignant. Ann Diagn Pathol. 2016 Feb; 20: 19–23. doi: 10.1016/j.anndiagpath.2015.10.010.

12. Du L., Wang H., He L., Zhang J., Ni B., Wang X., Jin H., Cahuzac N., Mehrpour M., Lu Y., Chen Q. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 2008; 14(21): 6751–60. doi: 10.1158/1078-0432.CCR-08-1034.

13. Nagano O., Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci. 2004; 95(12): 930–5. doi: 10.1111/j.1349-7006.2004.tb03179.x.

14. Harada N., Mizoi T., Kinouchi M., Hoshi K., Ishii S., Shiiba K., Sasaki I., Matsuno S. Introduction of antisense CD44S CDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. Int J Cancer. 2001 Jan 1; 91(1): 67–75. doi: 10.1002/1097-0215(20010101)91:1<67::aidijc1011>3.0.co;2-d.

15. Dallas M.R., Liu G., Chen W.C., Thomas S.N., Wirtz D., Huso D.L., Konstantopoulos K. Divergent roles of CD44 and carcinoembryonic antigen in colon cancer metastasis. FASEB J. 2012 Jun; 26(6): 2648–56. doi: 10.1096/fj.12-203786.

16. Ropponen K.M., Eskelinen M.J., Lipponen P.K., Alhava E., Kosma V.M. Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis. Scand J Gastroenterol. 1998 Mar; 33(3): 301–9. doi: 10.1080/00365529850170900.

17. Lingala S., Cui Y.Y., Chen X., Ruebner B.H., Qian X.F., Zern M.A., Wu J. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Exp Mol Pathol. 2010 Aug; 89(1): 27–35. doi: 10.1016/j.yexmp.2010.05.005.

18. Kojima M., Ishii G., Atsumi N., Fujii S., Saito N., Ochiai A. Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci. 2008 Aug; 99(8): 1578–83. doi: 10.1111/j.1349-7006.2008.00849.x.

19. Zhao P., Li Y., Lu Y. Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer. 2010 May 20; 10: 218. doi: 10.1186/1471-2407-10-218.

20. Horst D., Kriegl L., Engel J., Kirchner T., Jung A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest. 2009 Oct; 27(8): 844–50. doi: 10.1080/07357900902744502.

21. Tan Y., Chen B., Xu W., Zhao W., Wu J. Clinicopathological significance of CD133 in lung cancer: A meta-analysis. Mol Clin Oncol. 2014 Jan; 2(1): 111–115. doi: 10.3892/mco.2013.195.

22. Sagakyants A.B., Frantsiyants E.M., Zlatnik E.Yu., Gevorkyan Y.A., Soldatkina N.V., Bondarenko E.S., Samoylenko N.S., Ulyanova E.P., Shulgina O.G., Dashkov A.V., Kaymakchi D.O., Egorov G.Y., Grechkin F.N. Expression of markers of tumor stem cells in different forms of gastric cancer. Modern problems of science and education. 2018; 5. [Internet]. URL: http://www.science-education.ru/article/view?id=28129 (cited 28.05.2019). (in Russian).